PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
February 2, 2026Journal for ImmunoTherapy of CancerOpen Access

Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HVHollis VirayCMCharlene MantiaOJOpeyemi A Jegede

Discussion

Loading...

Member takes

Overview

A comprehensive analysis shows nivolumab plus cabozantinib improves survival outcomes in advanced renal cell carcinoma, indicating potential treatment benefits.

Key Points

  • This research aims to analyze overall survival and treatment experiences of patients with advanced renal cell carcinoma on different therapies.
  • Conducted a comparative analysis of nivolumab plus cabozantinib versus sunitinib in 651 patients with advanced renal cell carcinoma.
  • Partitioned survival analysis categorized time spent on different phases of treatment and recovery.
  • Utilized Kaplan-Meier curves to estimate areas corresponding to overall survival and treatment-free survival.
  • At 4 years, overall survival was 49.2% for nivolumab plus cabozantinib vs. 40.2% for sunitinib.
  • 17.6% of patients on nivolumab plus cabozantinib experienced treatment-free survival compared to 4.7% on sunitinib.
  • Patients with nivolumab plus cabozantinib spent significantly longer time on first-line therapy and had less survival time post-second-line therapy initiation.

Cite This Study

Viray et al. (2026) studied this question.

synapsesocial.com/papers/6980ff37c1c9540dea812043https://doi.org/10.1136/jitc-2025-013546
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC).2024 · 2 citations
  2. 2Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 2142024 · 23 citations
  3. 3Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)2024 · 7 citations
  4. 48 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial2024 · 3 citations
  5. 5Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial2024 · 99 citations